PROVISION Study Which Met Its Primary Endpoint Now Demonstrates Similar Clinical Outcomes for FFRangio and FFR

PROVISION Study, Prospective Randomized Trial Evaluating Clinical Outcomes of FFRangio Versus FFR Guidance, Demonstrates Similar MACE Rates at One Year
PARIS, May 22, 2025 /PRNewswire/ -- Today at the annual EuroPCR conference taking place in Paris, France, Dr. Toru Tanigaki of Gifu Heart Center in Gifu, Japan presented the one-year results of the physician-initiated PROVISION1 Study. At TCT 2024, investigators shared that the PROVISION Study met its non-inferiority primary endpoint and revealed economic and resource utilization advantages for the FFRangio technology over traditional invasive FFR.
The PROVISION Study is the first Japanese prospective randomized controlled trial (RCT) comparing the outcomes of an angio-based technology compared to invasive wire-based physiology and enrolled 401 patients across 13 centers in Japan. Patients with intermediate coronary lesions (30-90% diameter stenosis) were randomized 1:1 to either the wire-based FFR arm, in which the treatment decision was determined based on FFR values obtained using an invasive pressure wire, or the FFRangio arm, in which the treatment decision was based on FFRangio values. Based on the functional evaluations, either revascularization (PCI) and optimal medical management (OMT) or OMT alone were selected, and patients were followed clinically for at least one year.
During a Hotline / Late-Breaking Trials session at EuroPCR 2025, Dr. Tanigaki presented the rates of major adverse cardiac events (MACE) at one year for patients treated according to FFRangio guidance versus FFR guidance. MACE was defined as a composite of death from any cause, nonfatal myocardial infarction (MI) or unplanned revascularization. MACE at one year was 9.9% for the FFRangio arm versus 12.6% for the FFR arm [HR 0.80 (0.42 to 1.51), p = 0.489]. MACE excluding periprocedural MI was 3.5% for the FFRangio arm versus 6.0% for the FFR arm [HR 0.58 (0.13 to 1.42), p = 0.167]. The rates of all-cause death, myocardial infarction and target vessel revascularization at one year were all similar in the FFRangio arm and FFR arm.
"The CathWorks FFRangio® System has already demonstrated the highest diagnostic accuracy compared to wire-based FFR among non-hyperemic indices and angio-based technologies. The FFRangio System not only eliminates the drawbacks of invasive wire-based technologies that have limited the overall adoption of physiology but also provides tools that optimize clinical decision making. With the addition of this new body of clinical evidence demonstrating patients treated according to FFRangio guidance have similar outcomes to those treated based on invasive FFR guidance while potentially reducing procedural resources and costs, we are truly embarking on a new era in physiology, transforming FFRangio into the new standard of care," said Ramin Mousavi, CathWorks President & CEO.
ABOUT CATHWORKS
CathWorks is the leader in digital health innovations that can improve the lives of patients globally. The CathWorks FFRangio® System combines artificial intelligence and advanced computational science, transforming how cardiovascular disease is diagnosed and treated. The FFRangio System obtains physiologic information from routine angiograms, eliminating the need for drug stimulation and invasive pressure wires. It provides physicians with quick and reliable intraprocedural FFRangio values for the entire coronary tree. For more information on CathWorks, visit www.cath.works and follow @CathWorks on LinkedIn.
1.
Prospective Randomized trial of clinical Outcomes of angiography-based fractional flow reserve guidance Versus wIre-baSed fractIOnal flow reserve guidance (PROVISION) study is an investigation of the Utility of Coronary Angiography (FFRangio) in Comparison to Coronary Fractional Flow Reserve (FFR) in the Determination of Treatment Planning and the Clinical Prognosis in Patients with Chronic Phase Coronary Artery Disease
Investors:Mike Fehermike.feher@cath.works
Media:Sarita Monicosarita.monico@cath.works
View original content to download multimedia:https://www.prnewswire.com/news-releases/provision-study-which-met-its-primary-endpoint-now-demonstrates-similar-clinical-outcomes-for-ffrangio-and-ffr-302462921.html
SOURCE CathWorks

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

6 hours ago

• Yahoo

NASA moon orbiter spies grave of crashed Japanese lunar lander (image)

When you buy through links on our articles, Future and its syndication partners may earn a commission. NASA's Lunar Reconnaissance Orbiter (LRO) has imaged the crash site of Resilience, a moon lander built and operated by the Tokyo-based company ispace. Resilience tried to touch down on June 5 in the center of Mare Frigoris (Sea of Cold), a volcanic region interspersed with large-scale faults known as wrinkle ridges. Mare Frigoris formed over 3.5 billion years ago as massive basalt eruptions flooded low-lying terrain, according to Mark Robinson, a lunar scientist for the company Intuitive Machines who is based in Phoenix, Arizona. Later, the wrinkle ridges formed as the crust buckled under the weight of the heavy basalt deposits. Shortly after Resilience's landing sequence, the ispace Mission Control Center was unable to establish communications with the spacecraft. The team determined that Resilience had likely been lost, a conclusion that was firmed up a few hours later. Also lost on landing was the Tenacious microrover, a small wheeled vehicle developed in Luxembourg by ispace's European subsidiary. Tenacious carried a piece of artwork on its front bumper — Mikael Genberg's "Moonhouse," a small replica of the red-and-white homes famous in Sweden. Related stories: — Private Japanese spacecraft crashes into moon in 'hard landing,' ispace says — Japan's Resilience moon lander aces lunar flyby ahead of historic touchdown try (photo) — Japan's Resilience moon lander arrives in lunar orbit ahead of June 5 touchdown Resilience left some telltale marks when it slammed into the moon on June 5, and LRO noticed them. "The dark smudge formed as the vehicle excavated and redistributed shallow regolith (soil); the faint bright halo resulted from low-angle regolith particles scouring the delicate surface," Robinson, the principal investigator for the Lunar Reconnaissance Orbiter Camera, told Inside Outer Space. The crash spot is roughly 1.5 miles (2.4 kilometers) from the landing site that ispace mapped out, to one decimal place, on its webpage. One decimal place in lunar latitude and longitude equals 19 miles (30 km), Robinson said. Resilience was ispace's second moon lander. The company's first such probe also crashed during its touchdown try, in April 2023. Scott Manley has more details on the Resilience crash; check out his video here.

Yahoo

9 hours ago

• Yahoo

24-Acre Minnetonka Complex Put Up for Sale by Boston Scientific (BSX)

Boston Scientific Corporation (NYSE:BSX) is one of the best stocks to buy. On June 10, the company announced that it is selling one suburban Twin Cities property and expanding another, mirroring a pattern of companies centralizing in fewer but more dynamic sites. BSX has placed its 226,000 square foot Minnetonka campus on the market, indicating the wind-down of its presence in that suburb. Meanwhile, it is enlarging its Maple Grove operations with a new 52,000 square foot buildout at its 79-acre Weaver Lake location. That $139.4 million development seems relatively small beside Boston Scientific's second Maple Grove site, which is a $170 million, 400,000 square foot facility where staff are expected to begin moving in before year's end. A surgeon examining a patient's brain in an operating room, paramedics nearby. CBRE's listing describes the Minnetonka property as containing labs, warehousing, and top-tier offices. Though no asking price is listed, county records place the combined 2025 value of four adjacent parcels at $14.8 million. Boston Scientific employed around 10,000 people in Minnesota as of March, including sites in Minnetonka, Maple Grove, and a sizable Arden Hills facility. The number of employees has roughly doubled over 15 years. Despite its Massachusetts roots, the company runs all eight of its divisions in Minnesota, including its flagship cardiology arm. The company did not respond to specific queries about the Minnetonka sale, including the functions housed there or implications for workforce downsizing. The real estate listing indicates the company may lease the site until mid-2026 but plans a complete exit thereafter. Boston Scientific Corporation (NYSE:BSX), a global player in medical device innovation, operates through its Cardiovascular and MedSurg segments to deliver advanced diagnostic and therapeutic technologies. While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo

16 hours ago

• Yahoo

NASA spacecraft around the moon photographs the crash site of a Japanese company's lunar lander

CAPE CANAVERAL, Fla. (AP) — A NASA spacecraft around the moon has photographed the crash site of a Japanese company's lunar lander. NASA released the pictures Friday, two weeks after ispace's lander slammed into the moon. The images show a dark smudge where the lander, named Resilience, and its mini rover crashed into Mare Frigoris or Sea of Cold, a volcanic region in the moon's far north. A faint halo around the area was formed by the lunar dirt kicked up by the impact. NASA's Lunar Reconnaissance Orbiter captured the scene last week. The crash was the second failure in two years for Tokyo-based ispace. Company officials plan to hold a news conference next week to explain what doomed the latest mission, launched from Cape Canaveral in January. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.